23.11

1.32% -0.31

Denali Therapeutics Inc (DNLI)

Overview News Price History Option Chain Financials Why DNLI Down? Discussions Forecast

Denali Therapeutics Inc stock is traded at $23.11, with a volume of 1.16M. It is down -1.32% in the last 24 hours and down -6.89% over the past month. Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Previous Close:

$23.42

Open:

$23.52

24h Volume:

1.16M

Relative Volume:

0.63

Market Cap:

$3.67B

Revenue:

$1.27M

Net Income/Loss:

$-508.02M

P/E Ratio:

-8.0224

EPS:

-2.8807

Net Cash Flow:

$-419.23M

1W Performance:

-0.77%

1M Performance:

-6.89%

6M Performance:

+14.12%

1Y Performance:

+61.50%

1-Day Range:

$22.64

$23.65

1-Week Range:

$22.52

$24.05

52-Week Range:

$12.58

$27.30

Denali Therapeutics Inc Stock (DNLI) Company Profile

Name

Denali Therapeutics Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

(650) 866-8547

Address

161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO

Employee

507

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

DNLI's Discussions on Twitter

Compare DNLI vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNLI Denali Therapeutics Inc	23.11	3.67B	1.27M	-508.02M	-419.23M	-2.8807
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-26-26	Reiterated	H.C. Wainwright	Buy
Feb-24-26	Initiated	Wolfe Research	Peer Perform
Jan-07-26	Resumed	UBS	Buy
Apr-10-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-07-25	Resumed	Morgan Stanley	Overweight
Feb-11-25	Initiated	Deutsche Bank	Buy
Jan-07-25	Initiated	Robert W. Baird	Outperform
Jan-03-25	Initiated	William Blair	Outperform
Dec-16-24	Upgrade	Stifel	Hold → Buy
Oct-10-24	Resumed	Raymond James	Mkt Perform
Oct-07-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-13-23	Initiated	Citigroup	Buy
Nov-20-23	Resumed	JP Morgan	Overweight
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Sep-06-23	Initiated	B. Riley Securities	Buy
Jan-30-23	Initiated	SVB Securities	Outperform
Dec-05-22	Initiated	Cowen	Outperform
Nov-02-22	Upgrade	BTIG Research	Neutral → Buy
Nov-02-22	Initiated	BofA Securities	Buy
Jun-23-22	Initiated	Berenberg	Buy
Dec-10-21	Resumed	Raymond James	Mkt Perform
Sep-21-21	Initiated	Oppenheimer	Outperform
Sep-01-21	Initiated	SMBC Nikko	Outperform
May-18-21	Initiated	UBS	Buy
Feb-26-21	Reiterated	H.C. Wainwright	Buy
Feb-10-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-11-20	Reiterated	H.C. Wainwright	Buy
Oct-16-20	Downgrade	BTIG Research	Buy → Neutral
Sep-14-20	Resumed	JP Morgan	Overweight
Aug-20-20	Reiterated	H.C. Wainwright	Buy
Mar-13-20	Upgrade	Evercore ISI	In-line → Outperform
Feb-28-20	Upgrade	Wedbush	Neutral → Outperform
Feb-24-20	Initiated	Jefferies	Buy
Feb-19-20	Initiated	Stifel	Hold
Jan-27-20	Upgrade	Goldman	Neutral → Buy
Sep-26-19	Initiated	Wedbush	Neutral
Sep-13-19	Initiated	Nomura	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-26-19	Initiated	H.C. Wainwright	Buy
Nov-15-18	Initiated	Cantor Fitzgerald	Overweight
Nov-12-18	Initiated	Janney	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Jan-02-18	Initiated	Evercore ISI	Outperform
Jan-02-18	Initiated	Goldman	Neutral
Jan-02-18	Initiated	JP Morgan	Overweight
Jan-02-18	Initiated	Morgan Stanley	Overweight

View All

Denali Therapeutics Inc Stock (DNLI) Latest News

Jul 23, 2026

DNLI Maintained by Morgan Stanley -- Price Target Raised to $36 - GuruFocus

Jul 23, 2026

Jul 22, 2026

Denali Therapeutics (DNLI) Heads To AAIC, Is The Stock Already Pricey? - Yahoo Finance

Jul 22, 2026

Denali Therapeutics stock trades steady as ALS program advances and cash position supports pipeline - AD HOC NEWS

Jul 22, 2026

Is Denali Therapeutics (DNLI) Overvalued After Its FDA Approval? - Yahoo Finance

Jul 22, 2026

Jul 19, 2026

Denali Therapeutics (DNLI) Heads To Alzheimer’s Conference As Valuation Questions Return - Sahm

Jul 19, 2026

Jul 18, 2026

Trading Systems Reacting to (DNLI) Volatility - Stock Traders Daily

Jul 18, 2026

Jul 17, 2026

Deutsche Bank Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35 - Moomoo

Jul 17, 2026

Jul 16, 2026

DENALI THERAPEUTICS INC. : DEUTSCHE BANK RAISES TARGET PRICE TO $35 FROM $31 - Bitget

Jul 16, 2026

Analysts’ Top Healthcare Picks: Denali Therapeutics (DNLI), Celcuity (CELC) - The Globe and Mail

Jul 16, 2026

Deutsche Bank Adjusts Price Target on Denali Therapeutics to $35 From $31, Maintains Buy Rating - marketscreener.com

Jul 16, 2026

Jul 15, 2026

Will Recent Setbacks Impact Growth Prospects of DNLI Stock? - Yahoo Finance

Jul 15, 2026

BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $31 - Moomoo

Jul 15, 2026

Jul 14, 2026

Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI) - The Globe and Mail

Jul 14, 2026

Denali Therapeutics (DNLI) Faces 12.4% Decline in Share Value - GuruFocus

Jul 14, 2026

Jul 13, 2026

Denali Therapeutics Price Target Announced at $29.00/Share by JP Morgan - Moomoo

Jul 13, 2026

Wedbush Raises Price Target on Denali Therapeutics to $26 From $20, Keeps Outperform Rating - Moomoo

Jul 13, 2026

Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $26 - Moomoo

Jul 13, 2026

Denali Therapeutics (DNLI) Secures Overweight Rating from JPMorg - GuruFocus

Jul 13, 2026

JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating By Investing.com - Investing.com Nigeria

Jul 13, 2026

BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - Stocktwits

Jul 13, 2026

JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating - Investing.com

Jul 13, 2026

H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $42 - Moomoo

Jul 13, 2026

Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's? -- Barrons.com - Moomoo

Jul 13, 2026

Jul 10, 2026

Denali Therapeutics (DNLI) Investor Day 2025 Summary - Quartr

Jul 10, 2026

T. Rowe Price’s 10% Stake and Avlayah Approval Could Be A Game Changer For Denali Therapeutics (DNLI) - Sahm

Jul 10, 2026

Jul 09, 2026

Denali CEO to keynote AAIC 2026, highlighting a... - Pluang

Jul 09, 2026

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier - The Manila Times

Jul 09, 2026

Denali CEO to open AAIC 2026 with brain-delivery plan for Alzheimer’s - Stock Titan

Jul 09, 2026

Denali Therapeutics stock hits 52-week high at $26.95 By Investing.com - Investing.com South Africa

Jul 09, 2026

Denali Therapeutics stock hits 52-week high at $26.95 - Investing.com

Jul 09, 2026

Jul 08, 2026

DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth? - Yahoo Finance

Jul 08, 2026

T. Rowe Price holds 10.2% of Denali Therapeutics (DNLI) in 13G/A - Stock Titan

Jul 08, 2026

Jul 06, 2026

Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart.com

Jul 06, 2026

DNLIDenali Therapeutics Inc Volatility & Greeks - Finviz

Jul 06, 2026

Jul 05, 2026

Denali Therapeutics (DNLI) Looks Fully Valued Following Its 32% 30 Day Rally - Sahm

Jul 05, 2026

Jul 03, 2026

Denali Therapeutics stock stays focused on pipeline progress. - ad-hoc-news.de

Jul 03, 2026

Jul 01, 2026

Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK - Barchart.com

Jul 01, 2026

Jun 29, 2026

Denali to sell priority review voucher for $195M cash boost - MSN

Jun 29, 2026

Jun 27, 2026

Enterprise value to EBIT forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView

Jun 27, 2026

Price to sales forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView

Jun 27, 2026